

#EXIT THE WHO

PANDEMIC

TREATY

INTERNATIONAL

HEALTH REGULATIONS



“WHO never publishes individual DOIs [declaration of interest], except after consultation with the Office of the Director-General.”



**The WHO has fallen victim
to neoliberal globalisation
and to the economic
interests of powerful
nations and the
transnational corporations**

Alison Katz
NGO "Independent WHO"
Former WHO employee





If it proves to be the case that authors of WHO guidance which promoted the use of certain drugs were being paid at the same time by the makers of those drugs for other work they were doing for these companies that is reprehensible and should be condemned in the strongest possible terms.”

Professor Chris Del Mar

Professor of Public Health at Bond University

**WHO’s Strategic Advisory Group of
Experts on Immunization (SAGE)
member and Cochrane reviewer**





bmj.com

- ▶ See a video to accompany this investigation at <http://bit.ly/c3eEh3>
- ▶ Read Deborah Cohen's previous investigation—Complications: tracking down the data on oseltamivir (*BMJ* 2009;339:b5387)

thebmj

BMJ 2010 ; 340 doi: <https://doi.org/10.1136/bmj.c2912> (Published 04 June 2010)
Cite this as: *BMJ* 2010;340:c2912

WHO and the pandemic flu “conspiracies”

Key scientists advising the World Health Organization on planning for an influenza pandemic had done paid work for pharmaceutical firms that stood to gain from the guidance they wrote. These conflicts of interest have never been publicly disclosed by WHO. **Deborah Cohen** and **Philip Carter** investigate

Was it appropriate for WHO to take advice from experts who had declarable financial and research ties with pharmaceutical companies producing antivirals and influenza vaccines?

Why was key WHO guidance authored by an influenza expert who had received payment for other work from Roche, manufacturers of oseltamivir, and GlaxoSmithKline, manufacturers of zanamivir?

WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics 2004

Prof. Karl Nicholson, Member of The European Scientific Working Group on Influenza (ESWI), Prof. Frederick Hayden, University of Virginia, Dr. Arnold Monto, University of Michigan

Prof Nicholson is on the **Roche** pharmaceutical Company Payroll. He conducted a randomised controlled trial on oseltamivir (Tamiflu) supported by **Roche** and also received travel sponsorship and honorariums from **GlaxoSmithKline and Roche** for consultancy work and speaking at international respiratory and infectious diseases symposiums. Also received consultancy fees by **Wyeth, Chiron, and Berna Biotech**

Prof Hayden paid by **Roche** for lectures and consultancy work for the company at the time the guidance was produced and published, also received payments from **GlaxoSmithKline** for consultancy and lecturing until 2002. He also served on WHO Strategic Advisory Committee on Immunization, Vaccines and Biologicals (SAGE) and Board of Wellcome Trust

Prof Monto received honorariums, consultancy fees, and research support from **GSK, Novartis, Roche, Baxter, Sanofi, MedImmune**, and consultancy fees and research (GlaxoSmithKline, \$3000 speakers fees in 2009) and also research funding from ViroPharma.

WHO did not publicly disclose any of these conflicts of interest when it published the 2004 guidance.



Prof. Karl Nicholson



Prof. Fred Hayden



Dr. Arnold Monto



&

ESWI

...scientists fighting influenza

Sponsors



WHO H1N1 Emergency Committee: Conflicts of Interest

* Acting Chair of the FDA's Vaccines and Related Biological Products Advisory Committee

* Consultant for GSK, Novartis, Roche, Baxter and Sanofi

* His research unit funding from Sanofi Pasteur for influenza vaccine trial conducted in 2007-2008



Prof Arnold Monto
University of Michigan



Prof Neil M. Ferguson
Imperial College, London

* Scientific Advisory Group for Emergencies (SAGE)(UK)
* Head of International Health Regulations (IHR) (2005) Emergency Steering Committee

* Consultant for Roche, Novartis, Baxter and GSK Biologicals

* Funding from Sanofi, Janssen, Thermo-Fischer Scientific

* Funding from Bill and Melinda Gates Foundation, Wellcome Trust, CEPI, GAVI,



Dr Nancy J. Cox

* Director of CDC's World Health Organization (WHO) Collaborating Center for Surveillance, Epidemiology and Control of Influenza, receives funding from International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for flu vaccine

* Past Director of the Influenza Division at the Centers for Disease Control and Prevention (CDC)



Prof Maria Zambon
Deputy Director Public Health England

* Member UK Scientific Advisory Group for Emergencies (SAGE)

* Deputy Director Public Health England

* Member of International Health Regulations (IHR) (2005) Steering Committee

* Co-Director of the NIHR Respiratory Health Protection Unit with Imperial College London

* UK Health Protection Agency Centre for Infection (Zambon Lab) funding sources, Sanofi, Novartis, CSL, Baxter and GSK.

* Publications funding: Bill and Melinda Gates Foundation Wellcome Trust

* Support of Jeremy J. Farrar (Wellcome Trust) and World Health Organization



Dr Keiji Fukuda

* Assistant Director-General WHO (2009 to 2016)
* Former chief of CDC Epidemiology and Prevention Branch, Influenza Division
* Hong Kong COVID-19 expert panel (2020 – pres)



Dr John Wood
National Institute for Biological Standards and Control, UK

NIBSC does contract research for Sanofi Pasteur, CSL, IFPMA, Novartis and Powdermed

International Health Regulations (IHR) Committee



Prof Arnold Monto,
University of Michigan

- * Acting Chair of the FDA's Vaccines and Related Biological Products Advisory Committee
- * Consultant for GSK, Novartis, Roche, Baxter and Sanofi
- * His research unit funding from Sanofi Pasteur for influenza vaccine trial conducted in 2007-2008



Prof Neil M. Ferguson
Imperial College, London

- * Scientific Advisory Group for Emergencies (SAGE)(UK)
- * Head of International Health Regulations (IHR) (2005) Emergency Steering Committee
- * Consultant for Roche, Novartis, Baxter and GSK Biologicals
- * Funding from Sanofi, Janssen, Thermo-Fischer Scientific
- * Funding from Bill and Melinda Gates Foundation, Wellcome Trust, CEPI, GAVI,



Dr Nancy J. Cox

- * Director of CDC's World Health Organization (WHO) Collaborating Center for Surveillance, Epidemiology and Control of Influenza
- * Past Director of the Influenza Division at the Centers for Disease Control and Prevention (CDC)



Prof Maria Zambon
Deputy Director Public Health England


- * Member UK Scientific Advisory Group for Emergencies (SAGE)
- * Deputy Director Public Health England
- * Member of International Health Regulations (IHR) (2005) Steering Committee
- * Co-Director of the NIHR Respiratory Health Protection Unit with Imperial College London
- * UK Health Protection Agency Centre for Infection (Zambon Lab) funding sources, Sanofi, Novartis, CSL, Baxter and GSK.
- * Publications funding: Bill and Melinda Gates Foundation Wellcome Trust
- * Support of Jeremy J. Farrar (Wellcome Trust) and World Health Organization



Masato Tashiro

- * Director, WHO Collaborating Centre for Reference and Research on Influenza
- * WHO Essential Reference Laboratory of GISRS





World Health Organization

Big Pharma Conflicts of Interests



World Health Organization

&

ESWI

...scientists fighting influenza

Sponsors



AstraZeneca 

Johnson & Johnson

NOVARTIS

NOVAVAX
Creating Tomorrow's Vaccines Today

sanofi

Genentech
IN BUSINESS FOR LIFE

Baxter

MedImmune

Seqirus
A CSL COMPANY

VIATRIS

Influenza Pandemic Plan: The Role of WHO and Guidelines for National and Regional Planning

R Snacken, A. Osterhaus, J Wood, L R Haaheim, A P Kendal, G J Ligthart, and D Lavanchy

This document was prepared for the World Health Organization (WHO), in collaboration with the **European Scientific Working Group on Influenza (ESWI)(1999)**.

Professor Abe Osterhaus, ESWI Chairman, conducted a **randomised controlled trial on oseltamivir (Tamiflu), a trial funded by Roche**. He also served on WHO Strategic Advisory Committee on Immunization, Vaccines and Biologicals (SAGE)




Dr. René Snacken of the Belgian Ministry of Public Health, WHO Division of Viral Diseases wrote about studies involving neuraminidase inhibitors for a **Roche promotional booklet**.



Liaison officer for ESWI


Dr Daniel Lavanchy, **appeared at a Roche sponsored symposium in 1998** while Head of the WHO Global Influenza Program and Smallpox Program. Consultant to pharmaceutical industry.





Prof Albert Osterhaus


Albert Osterhaus: Global Elitist Hack



Viroclinics **D D L**
A Cerba Research Company

Co-Founder and Chairman of the Scientific Advisory Board **9.8% share**


Vaccine Development



World Health Organization

WHO Strategic Advisory Committee on Immunization, Vaccines and Biologicals (SAGE)

Director of the WHO Collaborating Centre for Arboviruses and Haemorrhagic Fever Reference and Research, Rotterdam (since 1995)



ESWI

Chair European Scientific Working Group on Influenza (ESWI)


Partner




CR20

Chief Scientific Officer


Vaccine Development





Erasmus MC
University Medical Center Rotterdam




Prof of Virology

Prof Albert Osterhaus

Board Member



Flublok®
QUADRIVALENT Influenza Vaccine

Vaccine development and Protein production




Protinhi Therapeutics

Treating Disease via Protease Inhibition

Scientific Advisory Board member

Partners



WORLDVACCINE CONGRESS WASHINGTON

Scientific Advisory Board



International One Health Coalition

Member




IDEVAX

Scientific Advisory Board member

Vaccine Development

Zoonoses vaccines



Chair/Initiator



Roche

Publication Funding



World Health
Organization

Ad Hoc Policy advisory SAGE Working Group on influenza A (H1N1) vaccines (April 2009 to April 2010)

SAGE Members	SAGE Experts	Institution	WHO Secretariat
David Salisbury, Chair Jon Abramson Supamit Chunsuttiwat	Nancy Cox Neil Ferguson Teeranart Jivapaisarnpong Paul-Henri Lambert Johannes Loewer Karen Midthun Phillip Minor Albert Osterhaus Stefania Salmaso Peter Smith	- Centers for Disease Control and Prevention, USA - Imperial College, UK - Ministry of Public Health, Thailand - Centre Médical Universitaire, Switzerland - Paul-Ehrlich Institut, Germany - WHO Global Advisory Committee on vaccine Safety, Center for Biologics Evaluation and Research, USA - WHO Expert Committee on Biological Standardization, National Institute for Biological Standards and Control, UK - Erasmus MC, Netherlands - WHO Global Advisory Committee on vaccine Safety, Istituto Superiore di Sanità, Italy - WHO Global Advisory Committee on vaccine Safety, London School of Hygiene and Tropical Medicine, UK	Marie-Paule Kieny Philippe Duclos

[About ESWI](#)

[Members and associate members](#)

[Financial supporters](#)

[Contact info](#)

The pharmaceutical companies supporting ESWI include:

› [AstraZeneca](#) (FluMist Quadrivalent Vaccine Manufacturer)

› [GlaxoSmithKline](#) (Zanamivir, H1N1 inhibitor)
(H1N1 Fluarix Quadrivalent Vaccine)

› [Roche](#) (Oseltamivir, H1N1 inhibitor)

› [Seqirus](#) (H1N1 Afluria Quadrivalent Vaccine)

› [Sanofi Pasteur](#) (H1N1 Fluzone Quadrivalent Manufacturer)

[Novartis](#) (Influenza A (H1N1) 2009 Monovalent Vaccine Manufacturer)

[Hofmann-La Roche](#) (H1N1 Vaccine Distributor)

[Baxter Vaccines](#) (H1N1 Vaccine Manufacturer)

[MedImmune](#) (H5N1 FluMist Quadrivalent Vaccine)

There are no exclusive rights to sponsorship. ESWI is pleased to discuss sponsorship opportunities with any organisation (commercial, non-profit, educational) interested in supporting and facilitating our long-term objectives. Potential sponsors are invited to contact the ESWI management: info@eswi.org

Protein Sciences Corporation
Package Insert

Quadrivalent Influenza Vaccine
BLA STN 125285

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Flublok[®] Quadrivalent safely and effectively. See full prescribing information for Flublok Quadrivalent.

Flublok Quadrivalent (Influenza Vaccine), Sterile Solution for Intramuscular Injection
2022-2023 Formula
Initial U.S. Approval: 2013

-----**INDICATIONS AND USAGE**-----

- Flublok Quadrivalent is a vaccine indicated for active immunization against disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine. Flublok Quadrivalent is approved for use in persons 18 years of age and older. (1)

-----**DOSAGE AND ADMINISTRATION**-----

For intramuscular (IM) injection only (0.5 mL). (2)

-----**DOSAGE FORMS AND STRENGTHS**-----

A sterile solution for injection supplied in 0.5 mL single dose prefilled syringes. (3)

-----**CONTRAINDICATIONS**-----

- Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine. (4, 6.2, 11)

-----**WARNINGS AND PRECAUTIONS**-----

- Appropriate medical treatment and supervision must be available to

manage possible anaphylactic reactions following administration of Flublok Quadrivalent. (5.1)

- If Guillain Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give Flublok Quadrivalent should be based on careful consideration of potential benefits and risks. (5.2)

-----**ADVERSE REACTIONS**-----

- In adults 18 through 49 years of age, the most common ($\geq 10\%$) injection-site reactions were tenderness (48%) and pain (37%); the most common ($\geq 10\%$) solicited systemic adverse reactions were headache (20%), fatigue (17%), myalgia (13%) and arthralgia (10%). (6.1)
- In adults 50 years of age and older, the most common ($\geq 10\%$) injection site reactions were tenderness (34%) and pain (19%); the most common ($\geq 10\%$) solicited systemic adverse reactions were headache (13%) and fatigue (12%). (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Sanofi Pasteur Inc., at 1-800-822-2463 (1-800-Vaccine) or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

-----**USE IN SPECIFIC POPULATIONS**-----

- **Pregnancy:** Pregnancy outcomes in women exposed to Flublok Quadrivalent during pregnancy are being monitored. Contact: Sanofi Pasteur Inc. by calling 1-800-822-2463. (8.1)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: xx/2022



ORIGINAL ARTICLE

Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections

Frederick G. Hayden, M.D., Albert D.M.E. Osterhaus, D.V.M., Ph.D., John J. Treanor, M.D., Douglas M. Fleming, F.R.C.G.P., Ph.D., Fred Y. Aoki, M.D., Karl G. Nicholson, M.D., Arthur M. Bohnen, M.D., Hilary M. Hirst, Oliver Keene, M.A., M.S., and Kevin Wightman, B.S. for the GG167 Influenza Study Group*

Abstract

BACKGROUND

The sialic acid analogue zanamivir (GG167) is a selective inhibitor of influenza A and B virus neuraminidases. These viral enzymes are essential for the release of virus from infected cells, and they may also reduce the inactivation of virus by respiratory secretions. When administered experimentally directly to the respiratory tract, zanamivir has potent antiviral effects. We assessed the therapeutic activity of zanamivir in adults with acute influenza.

Albert Osterhaus: Role in the Neuraminidase Conspiracy

Journal Title	Authors	Journal and Date	Funders
Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections	F.G. Hayden , A.D.M.E. Osterhaus , J.J. Treanor, D.M. Fleming, Fred Y. Aoki, K.G. Nicholson , A.M. Bohnen, H.M. Hirst, O. Keene, and K. Wightman, the GG167 Influenza Study Group	September 25, 1997. N. Engl. J. Med 1997; 337:874-880	Glaxo Wellcome
Neuraminidase Inhibitors for Treatment of Influenza A and B Infections	Andrea G. Winqvist, Keiji Fukuda , Carolyn B. Bridges, Nancy J. Cox .	December 17, 1999. Morbidity and Mortality Weekly Report (CDC) 48(RR14);1-9	CDC
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group	K G Nicholson 1 , F Y Aoki, A D Osterhaus , S Trottier, O Carewicz, C H Mercier, A Rode, N Kinnersley, P Ward	May 27, 2000. Lancet, 2000;355(9218):1845-50	
Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008	F. Dijkstra, M. Jonges, R, van Beek, G.A Donker, F.G Schellevis, M. Koopmans , M.A.B van der Sande, A.D.M.E Osterhaus , C.A.B Boucher, G,F Rimmelzwaan, and A. Meijer	Dec 23, 2011. Open Virol J. 2011; 5: 154–162.	
Oseltamivir -resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009–2010	A. Meijer, Albert Osterhaus , Marion Koopmans et.al	Antiviral Research, Volume 92, Issue 1, October 2011, Pages 81-89	
Influenza Virus Resistance to Antiviral Therapy	Erhard van der Vries 1 , Martin Schutten, Pieter Fraaij, Charles Boucher, Albert Osterhaus	2013. Advances in Pharmacology Volume 67, 2013, Pages 217-246	
Global Assessment of Resistance to Neuraminidase Inhibitors, 2008–2011: The Influenza Resistance Information Study (IRIS)	R. J. Whitley, C. A. Boucher, B. Lina, J. S. Nguyen-Van-Tam, Albert Osterhaus , M. Schutten, Arnold S. Monto	1 May 2013. Clinical Infectious Diseases, Volume 56, Issue 9,, Pages 1197–1205,	Roche, GlaxoSmithKline

About Roche

Solutions

Innovation

| Stories

Tamiflu (oseltamivir)


Tamiflu is licensed for the treatment of influenza in adults and children, and the prevention of influenza in adults and children one year of age and older. Tamiflu is an oral neuraminidase inhibitor (NAI) that acts by stopping the influenza virus from spreading and is active at sites in the body where the virus multiplies.



Tamiflu[®] 45 mg
hard capsules
Oseltamivir

45 mg

Oral use



10 capsules





[Behind the science magazine](#)

[Company](#)

[Innovation](#)

[Products](#)


[Responsibility](#)

[Investors](#)

[Media](#)

[Careers](#)

[Home](#) > [Media](#) > [Press releases](#) > [GSK receives a positive CHMP opinion ...](#)

 01 March 2019

GSK receives a positive CHMP opinion for intravenous zanamivir for the treatment of complicated influenza



Albert Osterhaus: Patents and Conflicts of Interest

Patent Description	Application Number	Filed Date	Inventors
A human monoclonal antibody blocking SARS-CoV-2 infection	2003632.3	March 12, 2020	Chunyan Wang, Wentao Li, Dubravka Drabek, Nisreen M. A. Okba, Rien van Haperen, Albert D. M. E. Osterhaus, Frank J. M. van Kuppeveld, Bart L. Haagmans, Frank Grosveld & Berend-Jan Bosch
Human Betacoronavirus Lineage C and Identification of N-Terminal Dipeptidyl Peptidase As Its Virus Receptor	17/027,295	September 21, 2020	Bartholomeus Leonardus Haagmans, Theodorus Marinus Bestebroer, Sander van Boheemen, Ronaldus Adrianus Maria Fouchier, Albertus Dominicus Marcellinus Erasmus Osterhaus, Ali Moh Zaki, Victor Stalin Raj, Berend Jan Bosch
Virus causing respiratory tract illness in susceptible mammals	11162148	December 30, 2019	Jan Cornelius De Jong, Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D. M. E. Osterhaus, Jan Groen
Influenza vaccine	10485863	July 25, 2011	Albertus D. M. E. Osterhaus, Bror Morein, Karin Lövgren Bengtsson
Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus	20100297730	December 22, 2008	Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Aurelia Haller, Roderick Tang
Mammalian positive-sense single stranded RNA virus (SARS) within the group of coronaviruses and components thereof.	10/552,755	Apr 8, 2004	Bartholomeus Haagmans, Thijs Kuiken, Ronaldus Fouchier, Albertus Dominicus Osterhaus

One Health Platform

Division	Date	Region served	Committed amount
Global Growth & Opportunity	MARCH 2018		\$150,360
Grant topic	Duration (months)	Grantee location	
Agricultural Development	13	Berlare, Antwerp, Belgium	

8



“Their Man on the Inside”



Tedros Adhanom Ghebreyesus: “Prostituting himself”

 World Health Organization	Director-General	
 The Global Fund	Chair (2009 to 2011)	
 Gavi The Vaccine Alliance	The High Level Taskforce on Innovative Financing for Health Systems	M e m b e r
Board Member		
 UNAIDS	Chair, Coordinating Board	
 IHME Institute for Health Metrics and Evaluation	 Member	
 CLINTON FOUNDATION		Harvard School of Public Health
Associate	Advisory Board	



Fig. Bill Gates and Tedros Adhanom Gherbreyesus



**“I met with the Bill and Melinda Gates Foundation and Emmanuel Macron, French president to get funding totalling 7.4 billion euros in pledges from the Global Fund to research and for the distribution of vaccines against COVID-19”
Dr Tedros Ghebreyesus, WHO Director-General (6 May 2020)**

Lui Spot

Dr Tedros Adhanom Ghebreyesus

The Tigray People's Liberation Front (TPLF) and Dr Tedros Adhanom Ghebreyesus

Table: The United States has classified the TPFL as a Tier III terrorist organization.

199008020002	1990-08-02	Ethiopia	Kobo district	Tigray Peoples Liberation Front (TPLF)	17	0	Religious Figures/Institutions	Sub-Saharan Africa	Armed Assault	Firearms
198802180001	1988-02-18	Ethiopia	Unknown	Tigray Peoples Liberation Front (TPLF)	0	0	Private Citizens & Property,NGO	Sub-Saharan Africa	Hostage Taking (Kidnapping)	Firearms
198410190003	1984-10-19	Ethiopia	Lalibela	Tigray Peoples Liberation Front (TPLF)	200	200	Private Citizens & Property	Sub-Saharan Africa	Hostage Taking (Barricade Incident)	Unknown
198308030001	1983-08-03	Ethiopia	Jari	Tigray Peoples Liberation Front (TPLF)	0	0	NGO	Sub-Saharan Africa	Hostage Taking (Kidnapping)	Unknown
198304200006	1983-04-20	Ethiopia	Korem	Tigray Peoples Liberation Front (TPLF)	Unknown	Unknown	NGO,NGO,NGO	Sub-Saharan Africa	Hostage Taking (Kidnapping)	Unknown
197905020020	1979-05-02	Ethiopia	Workamba	Tigray Peoples Liberation Front (TPLF)	100	0	Private Citizens & Property	Sub-Saharan Africa	Unknown	Unknown
197905020019	1979-05-02	Ethiopia	Aksum	Tigray Peoples Liberation Front (TPLF)	Unknown	Unknown	Private Citizens & Property	Sub-Saharan Africa	Armed Assault	Unknown,Unknown



Dr Tedros Adhanom Ghebreyesus

* listed in the U.S. Homeland Security Global Terrorism Database

Positions Held:

Executive Member of the Tigray People's Liberation Front

Ethiopian Minister of Foreign Affairs

Ethiopian Minister of Federal Ministry of Health

<https://vaccineimpact.com/2020/is-w-h-o-director-tedros-a-terrorist-global-ties-to-bill-gates-clinton-foundation-dr-fauci-china-and-genocide/>

https://www.uscis.gov/sites/default/files/USCIS/Laws/TRIG/2014_Implementation_of_New_Discretionary_Exemption_for_Activities_or_Associations_Relating_to_TPLF.pdf

WHO Chief Was Leader of Group Designated 'Terrorists' by U.S. Government

Dr. Tedros Adhanom Ghebreyesus led group qualified as 'Tier III terrorist organization'

By: Jay Greenberg | [@NeonNettle](#) on 23rd April 2020 @ 7.00pm



Dr. Tedros Adhanom Ghebreyesus was the leader of a political group designated a 'terrorist organization'

Tedros Ghebreyesus, was leader of Ethiopia's brutal minority party, the Tigray People's Liberation Front, a wing of the ruling Marxist-rooted Ethiopian People's Revolutionary Democratic Front (EPRDF). The TPLF is designated and qualifies as a Tier III terrorist organization under INA section 212(a)(3)(B)(vi)(III) (United States Department of Homeland Security) on the basis of its violent activities before it became part of the ruling coalition and the government of Ethiopia in May 1991.

Birhanu Jula, a general with the Ethiopian army, recently (2020) accused Ghebreyesus of helping the rebel group Tigray People's Liberation Front (TPLF) procure weapons.

In a complaint filed at the International Criminal Court in The Hague, Nobel Prize nominee David Steinman has accused Ghebreyesus of supporting genocide in Ethiopia which involved the murder, detention and torture of many indigenous people, belonging to the Amhara, Konso, Oromo and Somali tribes.

WHO director was accused of covering up epidemics in 2017

WHO's Dr Maria D. Van Kerkhove: "Globalist Hack and Elitist Puppet"



Imperial College London
Prof Neil Ferguson
Senior Research Fellow
Honorary Lecturer



World Health Organization

JPMORGAN CHASE & CO. Rockefeller Brothers Fund
Philanthropy for an Interdependent World

Google.org facebook. Eisai STATE STREET
Pfizer The Pfizer Foundation
Baxter International Foundation
MSD INVENTING FOR LIFE

COVID-19 Solidarity Response Fund

gsk Johnson & Johnson GE Foundation

THE WORLD BANK IBRD · IDA

Bloomberg Philanthropies INSTITUT PASTEUR
Post-Doctoral Fellow



Dr Maria D. Van Kerkhove
COVID-19 Technical Lead of the World Health Organization (WHO)

DFID Department for International Development

CONSIZE CONSORTIUM FOR THE STANDARDIZATION OF INFLUENZA SEROEPIDEMIOLOGY

UKRI Medical Research Council

LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE
PhD Degree



wellcome



CDC
CENTERS FOR DISEASE CONTROL AND PREVENTION



Stanford MEDICINE
Masters Degree



CORNELL UNIVERSITY
FOUNDED A.D. 1865
Undergraduate Degree

BILL & MELINDA GATES foundation

NIH Fogarty National Institutes of Health



unicef

The Corporatization of the WHO: A Question of Independence?



COVID-19 Solidarity Response Fund

FUND SUPPORTERS



9

International Health Regulations Committee (IHR)

Conflicts of Interest

International Health Regulations (IHR) Committee



Prof Arnold Monto,
University of Michigan

* Acting Chair of the FDA's Vaccines and Related Biological Products Advisory Committee

* Consultant for GSK, Novartis, Roche, Baxter and Sanofi

* His research unit funding from Sanofi Pasteur for influenza vaccine trial conducted in 2007-2008



Prof Neil M. Ferguson
Imperial College, London

* Scientific Advisory Group for Emergencies (SAGE)(UK)
* Head of International Health Regulations (IHR) (2005) Emergency Steering Committee

* Consultant for Roche, Novartis, Baxter and GSK Biologicals

* Funding from Sanofi, Janssen, Thermo-Fischer Scientific

* Funding from Bill and Melinda Gates Foundation, Wellcome Trust, CEPI, GAVI,



Dr Nancy J. Cox

* Director of CDC's World Health Organization (WHO) Collaborating Center for Surveillance, Epidemiology and Control of Influenza

* Past Director of the Influenza Division at the Centers for Disease Control and Prevention (CDC)



Prof Maria Zambon
Deputy Director Public Health England

* Member UK Scientific Advisory Group for Emergencies (SAGE)

* Deputy Director Public Health England

* Member of International Health Regulations (IHR) (2005) Steering Committee

* Co-Director of the NIHR Respiratory Health Protection Unit with Imperial College London

* UK Health Protection Agency Centre for Infection (Zambon Lab) funding sources, Sanofi, Novartis, CSL, Baxter and GSK.

* Publications funding: Bill and Melinda Gates Foundation Wellcome Trust

* Support of Jeremy J. Farrar (Wellcome Trust) and World Health Organization





Masato Tashiro

* Director, WHO Collaborating Centre for Reference and Research on Influenza

* WHO Essential Reference Laboratory of GISRS

Prof Neil Ferguson: Covid Modeller and Major Conflicts of Interest





H.E. Dr Gro Harlem Brundtland

Co-Chair, GPMB; Former Prime Minister, Norway and Former Director-General, World Health Organization Bilderberger (1983)



Mr Elhadj As Sy

Co-Chair, GPMB, Secretary-General, International Federation of Red Cross and Red Crescent Societies Wellcome Trust



H.E. Dr Diane Gashumba

Minister of Health, Republic of Rwanda



H.E. Sigrid Kaag

Minister for Foreign Trade and Development Cooperation, The Netherlands



Dr Victor Dzau

President, The National Academy of Medicine, USA Director of PepsiCo (2005). Advisor NIH



Dr Chris Elias

President, Global Development Program, Bill & Melinda Gates Foundation, USA



Professor Ilona Kickbusch

Director, Global Health Centre, Graduate Institute of International and Development Studies, Switzerland



H.E. Professor Veronika Skvortsova

Minister of Health, Russian Federation



Sir Jeremy Farrar

Director, Wellcome Trust, UK



Dr Anthony S. Fauci

Director, National Institute of Allergy and Infectious Diseases, USA



Dr Yasuhiro Suzuki

Chief Medical and Global Health Officer, Vice Minister for Health, Ministry of Health, Labour and Welfare, Japan



Dr Jeanette Vega Morales

Chief Medical Innovation and Technology Officer, La Red de Salud UC-Christus, Chile



Ms Henrietta Fore

Executive Director, UNICEF



Dr George F. Gao

Director-General, Chinese Center for Disease Control and Prevention, People's Republic of China



Professor K. VijayRaghavan

Principal Scientific Advisor to the Government of India



Wellcome Trust Ltd invested in Corporate Elite



Williams Burns

CEO of Roche Holdings, is one of the Board of Governors of Wellcome Trust



Elhadj As Sy

Co-chair of the WHO/World Bank Global Pandemic Preparedness Monitoring Board, and Board of Governors of Wellcome Trust



Dr Jeremy Farrar: 'Globalist Elitist Hack'

wellcome
sanger
institute

GENOME RESEARCH LIMITED

Chair of GRL Board

HM Government

UK Scientific
Advisory Group for
Emergencies (SAGE)

World Health
Organization

Advisor, WHO
Director-General

World Health
Organization

WHO Chief Scientist

World Health
Organization

Chair, WHO R&D
Blueprint Advisory
Group

WORLD
ECONOMIC
FORUM

Agenda Contributor

WEF Meeting
(2016-2023)

msc
Munich Security
Conference

Participant (2023)

THE
ROYAL
SOCIETY

Royal Fellow

HM Government

COVID-19 National Core
Studies (NCS) programme

Members of the
Oversight Committee

World Health
Organization

Member, Global
Preparedness
Monitoring Board

Jeremy Farrar
WHO Chief Scientist

World Health
Organization

ACTaccelerator
ACCESS TO COVID-19 TOOLS

Member, Principles
Group and
Facilitation Council

NTI BUILDING A SAFER WORLD

msc Munich Security Conference

CDC CENTERS FOR DISEASE CONTROL AND PREVENTION

World Health Organization

2021 Monkeypox
Tabletop Exercise

Participant (2021)

Partners

BILL & MELINDA GATES foundation

Open Philanthropy Project

farrar
foundation

A way into education, science, & sport

Chair and Founding Member

NIHR National Institute for
Health and Care Research

OSCHR (Office for
Strategic Coordination of
Health Research)

UKCDR

Strategic Coherence of
ODA-funded Research

Member of Board

1812
1823 1828
1928

The NEW ENGLAND
JOURNAL of MEDICINE

Advisory and
Editorial Board

wellcome

Former Director

CEPI

Founding
partner and
Board Member

Merck Johnson & Johnson AstraZeneca

wellcome

GHIT Fund

Global Health Innovative Technology Fund

Member of Council

BILL & MELINDA GATES foundation

外務省 MOFA Japan

ONO PHARMACEUTICAL CO., LTD. SHIONOGI Takeda Eisai

NATIONAL ACADEMY
OF SCIENCES

US Fellow

UKRI UK Research
and Innovation

VACCINE TASKFORCE UK

Member

gesda

Geneva Science and
Diplomacy Anticipator

Board of Directors

AGA KHAN FOUNDATION
An agency of the Aga Khan Development Network

Member of Board

The Academy of
Medical Sciences

Fellow

GLPID-R

GLOBAL RESEARCH COLLABORATION FOR
INFECTIOUS DISEASE PREPAREDNESS

Vice Chair

PRIME MINISTER'S OFFICE
SINGAPORE

Member, Research Funding
Advisory Board

Jeremy Farrar: Participant in 2021 Munich Security Conference – Global Elitist Hack

2021 NTI-MUNICH SECURITY CONFERENCE TABLETOP EXERCISE PARTICIPANTS

EXERCISE CO-CHAIRS

Dr. Ernest J. Moniz Co-Chair and CEO Nuclear Threat Initiative Former U.S. Secretary of Energy	Ambassador Wolfgang Ischinger Chairman Munich Security Conference
--	--

PARTICIPANTS

Mr. Arnaud Bernaert Head, Health Security Solutions SICPA	Ms. Angela Kane Visiting Professor Paris School of International Affairs (SciencesPo), and Tsinghua University
Dr. Beth Cameron Senior Director, Office of Global Health Security and Biodefense U.S. National Security Council	Dr. Emily Leproust CEO and Co-Founder Twist Biosciences
Mr. Luc Debruyne Strategic Advisor to the CEO Coalition for Epidemic Preparedness	Dr. Elisabeth Leiss Deputy Director of the Governance and Conflict Division German Corporation for International Cooperation (GIZ)
Dr. Ruxandra Draghia-Akli Global Head Johnson & Johnson Global Public Health R&D Janssen Research & Development	Ms. Izumi Nakamitsu Under-Secretary-General and High Representative for Disarmament Affairs United Nations Office for Disarmament Affairs
Dr. Chris Elias President, Global Development Division Bill & Melinda Gates Foundation	Dr. John Nkengasong Director Africa Centres for Disease Control and Prevention
Sir Jeremy Farrar Director Wellcome Trust	Sam Nunn Founder and Co-Chair Nuclear Threat Initiative Former U.S. Senator
Dr. George Gao Director-General, Chinese Center for Disease Control and Prevention (China CDC) Vice President, the National Natural Science Foundation of China (NSFC) Director and Professor, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences Dean, Medical School, University of Chinese Academy of Sciences	Dr. Michael Ryan Executive Director WHO Health Emergencies Programme
Dr. Margaret (Peggy) A. Hamburg Interim Vice President Global Biological Policy and Programs, Nuclear Threat Initiative Former Commissioner of the U.S. Food and Drug Administration	Dr. Joy St. John Executive Director CARPHA
	Dr. Petra Wicklandt Head of Corporate Affairs Merck KGaA



A Picture paints a 'Thousand Words'



Genocidal Maniac

**Co-Conspirator
Jeremy Farrar**
Director Wellcome Trust

Wellcome Trust Ltd invested in Corporate Elite

thebmj

covid-19

Research ▾

Education ▾

News & Views ▾

Campaigns ▾

Jobs

Feature » Investigation

Covid-19, trust, and Wellcome: how charity's pharma investments overlap with its research efforts

BMJ 2021 ; 372 doi: <https://doi.org/10.1136/bmj.n556> (Published 03 March 2021)

The major funder of health research stands to gain financially from the pandemic, raising questions about transparency and accountability

The BMJ finds, Wellcome itself holds investments in companies producing these same treatments. Financial disclosures from late 2020 show that Wellcome has a £275m (€318m; \$389m) stake in Novartis, which manufactures dexamethasone and is investigating additional therapeutics. And Roche, in which Wellcome holds a £252m stake, is helping to manufacture monoclonal antibodies with Regeneron. Both Roche and Novartis report having had conversations with WHO's ACT Accelerator about their therapeutic drugs

Wellcome also influences the pandemic response through Farrar's position on the Scientific Advisory Group for Emergencies advising the UK government on covid-19, as well as his board seat on the Coalition for Epidemic Preparedness Innovations, a leading public-private partnership in the pandemic that has pledged more than \$1bn to covid-19 vaccine development

Wellcome reports gains of £3.3bn from all investments in 2020, three times more money than the trust gave away in charity

Two investment companies on the calls with Farrar—Sequoia and Blackstone—have paid out dividends to Wellcome in recent years

Dr Jeremy Farrar: 'Globalist Elitist Hack'

Current Fellows



Jeremy Farrar OBE
FMedSci FRS

Elected 2015

THE
ROYAL
SOCIETY



Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Alejandro Cravioto (Chair)	Universidad Nacional Autónoma de México, Puerto Vallarta, Mexico	Bill & Melinda Gates Foundation. Wellcome Trust. Chief Scientific Officer of International Vaccine Institute (IVI). Executive Director. International Centre for Diarrhoeal Disease Research (icddr, USAID, NIH. CDC. Global Fund)
Dr Hanna Nohynek (Vice-Chair)	Chief Physician, Finnish Institute for Health and Welfare (Thl), Helsinki, Finland	Bill & Melinda Gates Foundation. PATH. Oxford University on ComCov studies. Grants from EU Commission. Expert advisor to European Medicines Agency. Honoraria for GSK and Pfizer. Finnish Institute for Health and Welfare receives funding from Sanofi Pasteur. GlaxoSmithKline.
Prof Shabir Madhi	Univ of the Witwatersrand, Johannesburg, SA	Funding from Pfizer, Minervax, GlaxoSmithKline , Novavax. Bill & Melinda Gates Foundation. International Vaccine Institute (IVI) Scientific Advisory Committee. BMGF Global Health Scientific Advisory Committee. Advisor to the Pfizer Group B streptococcal (GBS) vaccine program. Member of the DSMB of GSK and Janssen. Chair of the DSMB of CAPRISA. Clinical-Regulatory Advisory Board of CureVac for Covid-19 vaccine. National Principal Investigator, AstraZeneca ChAdOx-nCoV19 vaccine. Wits Health Consortium funded by Novartis, GSK, Medimmune, Novavax. Mitsubishi. Merck (MSD), Novavax .
Prof Peter McIntyre	Dunedin School of Medicine, Univ of Otago, Dunedin, New Zealand	Member of the DSMB for the Novavax Covid-19 vaccine. Member of the New Zealand Scientific and TAG on COVID-19 vaccines. Deputy Director of Australia's National Centre for Immunisation Research and Surveillance of Vaccine-Preventable Diseases (NCIRS). investigator on Wellcome Trust grant.

Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Anthony Scott	London School of Hygiene and Tropical Medicine. KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya	Funding from Wellcome Trust, Bill and Melinda Gates Foundation, National Institute for Health Research (NIHR). Worked with WHO and GAVI on vaccines. Joint Committee on Vaccination and Immunisation (JCVI) Board member. Director of the NIHR Health Protection Research Unit in Immunisation. Advisor to UK Health Security Agency. World Bank International Vaccines Task Force.
Prof Kathleen M. Neuzil	Director, Univ of Maryland School of Medicine, Baltimore, USA	Funding from Pfizer and NIH. Bill and Melinda Gates Foundation-funded Typhoid Vaccine Acceleration Consortium (2016-2021). CDC Advisory Committee on Immunization. Serum Institute of India, Ltd. Co-chair of the NIH COVID Vaccine Prevention Network. Univ of Maryland funding from GSK, Merck, Nosocomial Vaccine Corporation, ICON Clinical Research. Previous employment: PATH. Studied at Johns Hopkins University School of Medicine. Member on the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. Associate Editor of the journal Vaccine
Prof Kim Mulholland	Professor of Child Health and Vaccinology, London School of Hygiene and Tropical Medicine. Murdoch Children's Research Institute (MCRI), Melbourne, Australia	Safety Monitoring Committee from the Novavax Covid-19 Vaccine. Novavax Maternal RSV immunization project. PCV13 vaccination project on adult pneumonia in Mongolia funded by Pfizer. Principal Investigator in pneumococcal vaccine trials 1 and 2 funded by the Bill and Melinda Gates Foundation. Member of Gates Foundation DeCoDe Committee to review CHAMPS. Receives funding from GAVI.
Prof Noni MacDonald	Paediatrics, Dalhousie University, Halifax, Canada	Funding from Bill and Melinda Gates Foundation, WHO (Consultancy). Academic Committee Member of Leger, Canada. Board member of International Vaccine Institute. Member of the SAGE Working Group on Vaccine Hesitancy

Current SAGE Board Members/Conflicts of Interest

SAGE Member	Employment	Conflicts of Interest
Prof Rakesh Aggarwal	Director, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India	MSc from London School of Hygiene and Tropical Medicine
Dr Jaleela Jawad	Consultant, Ministry of Health Manama, Bahrain	CDC USA
Dr Sonali Kochhar	Assoc Prof, Univ of Washington, Seattle, USA	Funding from Bill & Melinda Gates Foundation, Wellcome Trust.
Prof Punnee Pitisuttithum	Mahidol University, Bangkok, Thailand	Safety Monitoring Committee for the U.S. Military HIV Research Program. Principal investigator Safety of Tri Fluvac influenza vaccine and MSD-funded 9vHPV vaccine.
Dr Folake Olayinka	Immunization Team Leader, USAID (Public Health Institute STAR Fellow). Washington, USA	Advisor to the WHO-AFRO Regional Immunization Technical Advisory Group.
Dr Ezzeddine Mohsni	Programme Essaha Aziza, European Union Tunis, Tunisia	Funding from Bill and Melinda Gates Foundation, Gavi and WHO.
Dr Ilesh V. Jani	Director General, National Institute of Health, Marracuene, Mozambique	Funding from CEPI and Bill and Melinda Gates Foundation, Janssen Vaccines & Prevention B.V., US National Institutes of Health (NIH), the HIV Vaccine Trial Network (HVTN). Grant/research support from WHO
Prof Andrew Pollard (former member)	Director of the Oxford Vaccine Group	Chief investigator for the Oxford-AstraZeneca COVID-19 vaccine clinical trials. Chair, Joint Committee on Vaccination and Immunisation (JCVI), Chair Scientific Advisory Group on Vaccines at the European Medicines Agency, National Institute for Health and Care Excellence (NICE, UK). Senior Advisor to the Medicines and Healthcare Products Regulatory Agency (MHRA) Panel, Advisor to the European Medicine Agency (EMA). Lead developer of the Bexsero meningococcal B vaccine, previously owned by Novartis and now owned by GSK. Funding from Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI),

WHO guideline on country pharmaceutical pricing policies 2020

Guideline Development Group Members

Member	Position	Conflicts of Interest/Funding	Conflicts of Interest/Position
YingYao Chen	Director, Key Lab of Health Technology Assessment Fudan University, China	Bristol-Myers Squibb, Medtronic, Braun, Edwards, BGI, Roche Diagnostics	Advisory Group for John Hopkins Bloomberg School of Public Health,
Andrew Hill	Senior Visiting Research Fellow Department of Pharmacology and Therapeutics, The University of Liverpool, the United Kingdom	Merck, Janssen, Bill and Melinda Gates Foundation, USAID, NIH, Wits RHI, Rainwater Charitable Foundation, Unitaid,	WHO consultant, Advisor to Bill and Melinda Gates Foundation, Advisor to Clinton Health Access Initiative, Roche employee,
Shadi Saleh	Founding Director Global Health Institute, American University of Beirut, Beirut, Lebanon	Novartis and Janssen Pharmaceuticals	Advisor to World Bank, WHO and UN on health care financing policy
Fatima Suleman	Chairperson, National Medicines Pricing Committee National Department of Health, University of KwaZulu-Natal, Durban, South Africa	World Health Organization, consulting firm HERA, and South African National Department of Health	Director: World Health Organization Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice at Univ Kwazulu-Natal, Fulbright Scholar 2002-2004
Sabine Vogler	Head of the Pharmacoeconomic Department, Austrian National Public Health Institute, Vienna, Austria	BioMérieux, Janssen, Abbott, BioRad, Wellcome Trust, Accelerate Diagnostics S.L, BD Switzerland Sàrl	Head of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Gesundheit Österreich GmbH

Final ACT-A Facilitation Council composition¹

Governments

Co-Chairs: Norway and South Africa

Regional groups

- League of Arab States: Bahrain
- Association of South East Asian Nations (ASEAN): Vietnam
- African Union (AU): South Africa
- Caribbean Community (CARICOM): Saint Kitts and Nevis
- Commonwealth of Independent States (CIS): Uzbekistan
- Forum of Small States: Singapore
- New Partnership for Africa's Development (NEPAD): Rwanda
- Community of Latin American and Caribbean States (CELAC): Mexico³
- Pacific Island Forum (PIF): Tuvalu
- South Asian Association for Regional Cooperation: Nepal

Founding Donors

- Canada
- France
- Germany
- Italy
- Japan
- Norway
- Saudi Arabia
- Spain
- United Kingdom

Market Shapers²

- Brazil
- China
- India
- Indonesia
- Republic of Korea
- Russia

Co-hosts

- World Health Organization & European Commission

Non-government partners

- Bill & Melinda Gates Foundation
- Wellcome Trust
- World Economic Forum

Envoys & Invitees

- WHO Envoys x2
- CSO x 2
- ICC

¹ USA & World Bank observers to the Council meeting

² South Africa is also a market shaper & founding member

³ founding member



World Health Organization

BILL & MELINDA GATES foundation



Corruption: World Health Organisation under scrutiny



WORLD HEALTH ORGANIZATION

EXECUTIVE BOARD

107th Session

Provisional agenda item 8.3

EB107/20

30 November 2000

Guidelines on working with the private sector to achieve health outcomes

Report by the Secretariat

Corruption: World Health Organisation under scrutiny



WORLD HEALTH ORGANIZATION

EXECUTIVE BOARD

107th Session

Provisional agenda item 8.3

EB107/20

30 November 2000

Guidelines:

13. WHO should avoid indirect collaboration (particularly if arranged by a third party acting as an intermediary between WHO and a commercial enterprise)

Corruption: World Health Organisation under scrutiny

thebmj

covid-19

Research ▾

Education ▾

News & Views ▾

Campaigns ▾

Feature » Drug industry sponsorship

Who's funding WHO?

BMJ 2007 ; 334 doi: <https://doi.org/10.1136/bmj.39119.519664.BE> (Published 15 February 2007)

Cite this as: *BMJ* 2007;334:338

WHO guidelines state that it will not accept money from drug companies, but how rigorous is it in enforcing this? Michael Day investigates

In the email dated 16 June 2006, Dr Benedetto Saraceno (director of WHO's Department of Mental Health and Substance Abuse) thanks Mary Baker of the European Parkinson's Disease Association (EPDA), "for raising the \$10 000 from GlaxoSmithKline (on WHO's behalf)" "requested by the WHO." "Unfortunately," he says, "WHO cannot receive funds from pharmaceutical industry. Our legal Office will reject the donation. Therefore, I suggest that this money should be given to EPDA."

The sum was then to be passed on to WHO—ostensibly with the intention of obscuring the origins of the donation.

Serious questions have been raised about whether the World Health Organization is using patient groups as a conduit for receiving proscribed donations from the pharmaceutical industry. Email correspondence passed to the *BMJ* seems to show that in June 2006 Benedetto Saraceno, the director of WHO's department of mental health and substance abuse, suggested that a patient group should accept a donation from GlaxoSmithKline (GSK) on behalf of the WHO. Saraceno's suggestion was made "with the intention of obscuring the origins of the donation." The money was to have funded a report on neurological diseases, including Parkinson's disease, for which GSK produces treatments.

When asked about this correspondence, Dr Saraceno told the *BMJ* that his email to the patient organisation was "clumsily worded" and that he had "never intended to solicit donations from the pharmaceutical industry through the patient organisation. In the email dated 16 June 2006, Dr Saraceno thanks Mary Baker of the European Parkinson's Disease Association (EPDA), for raising the \$10 000 "requested by the WHO." The money was to have funded a report on neurological diseases, including Parkinson's disease, for which GSK produces treatments.


Corruption: World Health Organisation under scrutiny

Conflict of Interest and Bias in Health Advisory Committees: A case study of the WHO's EMF Task Group

Maisch Don

JACNEM. Vol. 21. No. 1 pages 15 – 17. April 2006

The case of WHO, Michael Repacholi and the International Commission on Non-Ionizing Radiation Protection (ICNIRP)



Michael Repacholi
Head of International
EMF Project, WHO

1. Michael Repacholi, head of the WHO's International EMF Project, is also Chairman Emeritis of ICNIRP

“WHO's Repacholi declared that Mobile Telephone Masts and the microwave radiation (the EMFs) emitted by them and other such devices not to be dangerous.” (2007)

2. “Microwave News” reported that Repacholi, as head of the EMF Project, receives \$150,000 annually from the cellphone industry.
3. ICNIRP clearly states on its website that all commission members are independent Experts. ICNIRP also does not accept funding from industry. **The WHO failed to declare this obvious conflict of interest**

WHO: Controlling the Covid Narrative



NEWS INDEPENDENT TV POLITICS CLIMATE VOICES INDY100 SPORT CULTURE **INDY/LIFE** INDYBEST DAILY EDITION

UN whistleblower files complaint against WHO after pressure to falsify data about Italy's Covid plan

The U.N. epidemiologist who denounced the removal of a report on Italy's coronavirus response says he is suffering retaliation for having spoken out



Dr Francesco Zambon, former WHO employee

The W.H.O. press office denied Director-General Tedros was personally involved in killing the Zambon report

Emails and chat messages allegedly showed that former W.H.O. Assistant Director-General Dr. Ranieri Guerra, the organization's liaison to Italy during the coronavirus outbreak, actually made false statements as well as working to suppress the Zambon report because it embarrassed the Italian government.

Beijing used its influence within W.H.O. to prevent the organization from criticizing China or fully investigating the origins of the pandemic in China. Zambon told AFP

WHO: Controlling the Covid Narrative



EXCLUSIVE

COVID-19: Whistleblower claims WHO tried to force him to change report about Italy's pandemic protocols

falsify

Dr Francesco Zambon says the affair undermined the ability of governments globally to react to the pandemic more successfully.



Stuart Ramsay

Chief correspondent @ramsaysky

14 April 2021

“The report which was a global plan for Covid Response, never saw the light, says, Zambon.

“This affair has damaged the reputation of WHO. The lack of independence, transparency. The organisation is bound by personal interests, by government interference and financial powers.” says Zambon



Dr Francesco Zambon,
former WHO employee



Vaccine Misinformation: Statement by WHO Director- General on Facebook and Instagram

4 September 2019 | Statement | Geneva | Reading time: Less than a minute (266 words)

The World Health Organization welcomes the [commitment by Facebook](#) to ensure that users find facts about vaccines across Instagram, Facebook Search, Groups, Pages and forums where people seek out information and advice.

Facebook will direct millions of its users to WHO's accurate and reliable vaccine information in several languages, to ensure that vital health messages reach people who need them the most.

The World Health Organization and Facebook have been in discussions for several months to ensure people can access authoritative information on vaccines and reduce the spread of inaccuracies.

Vaccine misinformation is a major threat to global health that could reverse decades of progress made in tackling preventable diseases.

“We want digital actors doing more to make it known around the world that #VaccinesWork”

Statement by Dr Tedros Adhanom Ghebreyesus
WHO Director-General


WHO collusion in vaccine misinformation

WHO has also been working closely with social media and technology companies to help curb some of the misinformation spreading on their platforms. In February, officials from the health agency met at Facebook's headquarters about how to promote accurate health information about COVID-19. Now, WHO is working with more than 50 digital companies and social media platforms including TikTok, Google, Viber, WhatsApp, and YouTube to ensure that science-based health messages from the organization or other official sources appear first when people search for information related to COVID-19. Even the dating app Tinder now features WHO health reminders, because social distancing is still appropriate during a date.



World Health Organization

facebook



TikTok

Facebook collusion in censorship



How We're Taking Action Against Vaccine Misinformation Superspreaders

August 18, 2021

By Monika Bickert, Vice President, Content Policy



WHO Programme for International Drug Monitoring



World Health
Organization

VigiLyze

Global Signal Detection
and Management tool

VigiAccess

WHO's Adverse Events from
Immunization Reporting System



WHO Collaborating Centre for
International Drug Monitoring

VigiFlow

National Vaccine Safety Surveillance

VigiBase

WHO's global database for Adverse
Events from Immunization

WHO's Vaccine Advisory Committee



Founding and Permanent member of
the Gavi Board

VIPS Member



VIPS Member



VIPS Member

Collaboration between the Gavi Secretariat,
World Health Organization (WHO), Bill &
Melinda Gates Foundation (BMGF), United
Nations Children's Fund (UNICEF) and PATH



Vaccine Microarray Patches

Accelerate development and future uptake
of vaccine MAP products for LMIC use



VIPS Member

**BILL & MELINDA
GATES foundation**

VIPS Member

Develop a single integrated framework to evaluate and prioritise vaccine product innovations and to drive these innovations forward

VIPS Steering Committee members



















Members	Organisation	Role
Alejandro Cravioto	Facultad de Medicina Universidad Nacional Autónoma de México	Professor; SAGE Chair
David Robinson	Bill and Melinda Gates Foundation	Deputy Director of Vaccine Development and Surveillance, Chemistry Manufacturing and Controls
Christopher Morgan	Jhpiego (from June 2020) and Burnet Institute	Senior Technical Advisor (Immunization) and Honorary Senior Principal Research Fellow
David Kaslow	PATH	Vice president, Essential Medicines
Jean-Pierre Amorij	UNICEF Supply Division	Vaccine Technology Specialist
Jerome Kim	International Vaccine Institute	Director General
Jon Abramson	Wake Forest School of Medicine	Professor of Pediatric Infectious Diseases
Kelly Moore	Vanderbilt University School of Medicine	Adjunct Associate Professor of Health Policy
Mark Jit	London School of Hygiene and Tropical Medicine	Professor, Vaccine Epidemiology
Mark Papania	Global Immunization Division, Centers for Disease Control	Medical Epidemiologist
Michael Free	Independent	Independent Consultant; Senior Advisor Emeritus, PATH
Nora Dellepiane	QRB Consultants Sàrl	Independent consultant
Ramanan Laxminarayan	Center for Disease Dynamics, Economics and Policy	Director
Ruth Karron	John Hopkins University	Professor, International Health
Samir Sodha	WHO	Routine Immunization Officer
Shelley Deeks	Public Health Ontario	Chief, Health Protection Officer




WHO Immunisation Practices Advisory Committee member
 Product Development for Vaccines Advisory Committee member


WHO is in the Vaccine Business – Conflicts of Interest

 <p>givs global immunization vision and strategy</p> <p>To immunize more people, from infants to seniors, with a greater range of vaccines</p>	 <p>WHO-IVB World Health Organization</p> <p>WHO Immunization, Vaccinations and Biologicals Regulations</p> <p>Advise D-G on Vaccine Regulations</p>	 <p>World Health Organization</p> <p>Global Vaccine Action Plan (GVAP)</p> <p>Decade of Vaccines (2011–2020)</p> <p>BILL & MELINDA GATES foundation</p> <p>Funder</p>	 <p>SAGE World Health Organization</p> <p>Strategic Advisory Group of Experts on immunization</p> <p>Global policies and strategies on all vaccines, vaccine-preventable diseases and technology</p>
 <p>PSPQ-SC World Health Organization</p> <p>The Programmatic Suitability of Prequalified Vaccines Standing Committee</p> <p>Ensures continuing compliance with specifications and established standards of quality</p>	 <p>immunization action coalition</p> <p>IAC immunize.org</p> <p>IPAC World Health Organization</p> <p>Immunization Practices Advisory Committee</p> <p>Strengthen GVAP vaccine service delivery</p>	 <p>EPI World Health Organization</p> <p>Expanded Programme on Immunization</p> <p>Assessment - strengths and weaknesses of Immunization programmes</p>	 <p>IVIR-AC World Health Organization</p> <p>Immunization and Vaccines Related Implementation Research Advisory Committee</p> <p>Vaccine value assessments, research, effectiveness and impact studies</p>
 <p>PDVAC World Health Organization</p> <p>Product Development for Vaccines Advisory Committee</p> <p>Recommendations infectious disease pathogens, associated vaccine and monoclonal antibody product development</p>	 <p>ECBS World Health Organization</p> <p>Expert Committee on Biological Standardization</p> <p>Establish guidelines for manufacturing, licensing and control of vaccines, blood products and related in vitro diagnostic tests and biotechnology products</p>	 <p>GACVS World Health Organization</p> <p>Global Advisory Committee on Vaccine Safety</p> <p>Scientific advice to WHO on vaccine safety</p>	 <p>DCVMN Developing Countries Vaccine Manufacturers Network</p> <p>Developing Countries Vaccine Manufacturers Network</p> <p>Strengthen vaccine manufacturers technology transfer initiatives</p>
 <p>VP-WG World Health Organization</p> <p>Vaccine Prioritization Working Group</p> <p>Evaluate candidate COVID-19 vaccines for the WHO international Solidarity Trial Vaccines</p>	 <p>VPPAG World Health Organization</p> <p>Vaccine Presentation and Packaging Advisory Group</p> <p>Recommendations vaccine formulations, labelling, temp stability</p>	 <p>WHO EMP World Health Organization</p> <p>WHO Essential Medicines and Health Products Price</p> <p>Sets international standards for the manufacturing and regulation and harmonization aligned with SDG</p>	 <p>PIP FRAMEWORK</p> <p>Pandemic Influenza Preparedness Framework</p>

WHO is in the Vaccine Business – Conflicts of Interest




Vaccine Alliance Board: Major Conflicts of Interest



WORLD BANK

Juan Pablo Uribe
Global Director, Health, Nutrition & Population and the Global Financing Facility, World Bank




unicef

Omar Abdi
Deputy Executive Director UNICEF




World Health Organization

Bruce Aylward
Assistant Director-General WHO




World Health Organization

Awa Marie Coll Seck
Chairperson of Committee B of the World Health Assembly



CDC
CENTERS FOR DISEASE CONTROL AND PREVENTION

Anne Schuchat
Former Deputy Director



Rothesay

Naguib Kheraj
Chairman of Rothesay Life



BILL & MELINDA GATES foundation

Violaine Mitchell
Director, Health Funds and Partnerships




Gavi
The Vaccine Alliance

José Manuel Barroso
GAVI Chairman/Goldman Sachs Executive Chairman




Gavi
The Vaccine Alliance

Sarah Goulding
GAVI Vice-Chair
Assistant Secretary, Dept. Foreign Affairs and Trade, Australia




MERCK

Andrew (Drew) Otoo
President, Global Vaccines - Vaccines Industrialized



CLINTON HEALTH ACCESS INITIATIVE

Mphu Ramatlapeng
Executive Vice President
Clinton Health Access Initiative




BHARAT BIOTECH

Sai Prasad
President, Quality Operations
Vaccine industry - Developing

Interestingly, GAVI is also funded by the BMGF, which has donated USD 4.1 billion to date.

Vaccine Alliance: Major Conflicts of Interest

Gavi Board Chair: José Manuel Barroso





Vaccine Alliance: Major Conflicts of Interest

Gavi Board Member: Margaret Ann Hamburg



Margaret Ann Hamburg

Assistant Secretary

National Institute of Allergy and Infectious Diseases
NIH National Institutes of Health
Assistant Director

U.S. FOOD & DRUG ADMINISTRATION
FDA Commissioner

Member of the Global Health Scientific Advisory Committee

Chair of the Joint Coordinating Group

The ROCKEFELLER FOUNDATION

HENRY SCHEIN®
Board Director
U.S. distributor of flu vaccines and dental amalgam

Board of Trustees Member
THE ROCKEFELLER UNIVERSITY
Science for the benefit of humanity

Anylam®
Member of the Board of Directors
RNAi therapeutics

SANOFI
10% share

NOVARTIS
\$545M sharevalue

wellcome



Peter Fitzhugh Brown
Hamburg's Husband,
CEO Renaissance

Renaissance

TITAN PHARMACEUTICALS
61,913 shares
December 2015

Probuphine

Johnson & Johnson

MERCK

Abbott medco®

NTI
BUILDING A SAFER WORLD
Senior Scientist
Nuclear Threat Initiative

Member of the Strategic Advisory Board on
Vaccines and Drug-resistant Infections

AAAS
ADVANCING SCIENCE. SERVING SOCIETY
Chair of the Board

COUNCIL on FOREIGN RELATIONS
Member of the Board of Directors, Independent Task Force on Improving (Covid) Pandemic Preparedness, 2020

CSIS | CENTER FOR STRATEGIC & INTERNATIONAL STUDIES
senior fellow

Harvard University
Member of the Board of Fellows

GERM will cost the world around \$1 billion a year to cover salaries for the force of 3,000 people we'd need, plus equipment, travel, and other expenses—money that would come from governments.

WHO - Coordinator

GERM – Advisor and Reviewer

